التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_1_Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.docx |
| المؤلفون: |
Chengpei Zhu, Jingnan Xue, Yunchao Wang, Shanshan Wang, Nan Zhang, Yanyu Wang, Longhao Zhang, Xu Yang, Junyu Long, Xiaobo Yang, Xinting Sang, Haitao Zhao |
| سنة النشر: |
2023 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, advanced biliary tract cancer, lenvatinib, PD-1 inhibitor, PD-L1 inhibitor, Gemox chemotherapy |
| الوصف: |
Background Lenvatinib combined with anti-PD-1 antibodies and systemic chemotherapy has demonstrated a relatively high antitumor activity for intrahepatic cholangiocarcinoma in phase 2 clinical trials. However, its efficacy and safety in advanced biliary tract cancer (BTC) has not been reported in a real-world study. Methods Patients with advanced BTC who received lenvatinib combined with PD-1/PD-L1 inhibitors plus oxaliplatin and gemcitabine (Gemox) chemotherapy were retrospectively screened. The overall survival, progression-free survival, objective response rate, disease control rate, clinical benefit rate, and safety were evaluated. Results Fifty-seven patients with advanced BTC were included in the study. The median follow-up time was 15.1 (95% CI: 13.6–19.7) months. The median overall survival and progression-free survival were 13.4 (95% CI: 10.0–NA), and 9.27 (95% CI: 7.1–11.6) months, respectively. The objective response rate, disease control rate and clinical benefit rate were 43.9% (95% CI: 31.8%–56.7%), 91.2% (95% CI: 81.1%–96.2%), and 73.7% (95% CI: 61.0%–83.4%), respectively. Subgroup analysis revealed that the first-line treatment group had a longer median progression-free survival (12.13 vs. 6.77 months, P<0.01) and median overall survival (25.0 vs. 11.6 months, P=0.029) than the non-first-line treatment group. Moreover, three patients underwent conventional surgery after treatment. All patients (100%) experienced adverse events, and 45.6% (26/57) experienced grade 3 or 4 adverse events. The most commonly observed grade 3 or 4 adverse events was myelosuppression (7/57, 12.3%). No grade 5 adverse events were reported. Conclusion Lenvatinib combined with PD-1/PD-L1 inhibitors and Gemox chemotherapy represents an effective and tolerable treatment option in patients with advanced BTC. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/dataset/DataSheet_1_Efficacy_and_safety_of_lenvatinib_combined_with_PD-1_PD-L1_inhibitors_plus_Gemox_chemotherapy_in_advanced_biliary_tract_cancer_docx/21914124 |
| DOI: |
10.3389/fimmu.2023.1109292.s001 |
| الاتاحة: |
https://doi.org/10.3389/fimmu.2023.1109292.s001
https://figshare.com/articles/dataset/DataSheet_1_Efficacy_and_safety_of_lenvatinib_combined_with_PD-1_PD-L1_inhibitors_plus_Gemox_chemotherapy_in_advanced_biliary_tract_cancer_docx/21914124 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.7FD63240 |
| قاعدة البيانات: |
BASE |